Amgen (AMGN) : Oliver Luxxe Assets scooped up 467 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 3,849 shares of Amgen which is valued at $644,708.Amgen makes up approximately 0.51% of Oliver Luxxe Assets’s portfolio.
Other Hedge Funds, Including , Nadler Financial Group reduced its stake in AMGN by selling 19 shares or 0.9% in the most recent quarter. The Hedge Fund company now holds 2,092 shares of AMGN which is valued at $350,410. Amgen makes up approx 0.14% of Nadler Financial Group’s portfolio.Independence Advisors boosted its stake in AMGN in the latest quarter, The investment management firm added 1,888 additional shares and now holds a total of 3,393 shares of Amgen which is valued at $568,328. Amgen makes up approx 0.27% of Independence Advisors’s portfolio.New England Research Management reduced its stake in AMGN by selling 2,075 shares or 22.22% in the most recent quarter. The Hedge Fund company now holds 7,265 shares of AMGN which is valued at $1,214,999. Amgen makes up approx 1.02% of New England Research Management’s portfolio.Indiana Trust Investment Management Co reduced its stake in AMGN by selling 45 shares or 2.01% in the most recent quarter. The Hedge Fund company now holds 2,189 shares of AMGN which is valued at $366,088. Amgen makes up approx 0.19% of Indiana Trust Investment Management Co’s portfolio.Eqis Capital Management boosted its stake in AMGN in the latest quarter, The investment management firm added 8,761 additional shares and now holds a total of 30,295 shares of Amgen which is valued at $5,066,536. Amgen makes up approx 0.32% of Eqis Capital Management’s portfolio.
Amgen opened for trading at $167.94 and hit $168.1499 on the upside on Friday, eventually ending the session at $167.5, with a gain of 0.36% or 0.6 points. The heightened volatility saw the trading volume jump to 16,79,823 shares. Company has a market cap of $125,350 M.
On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.